Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Partially Remote
Drugs
Locations
Clinical Specialty
861-880 of 998 trials

Brain Aneurysms: Acetylsalicylic Acid Study

We are studying whether acetylsalicylic acid can lower the risk of stroke and improve cognitive function in patients undergoing treatment for unruptured brain aneurysms. This trial compares ASA with a placebo to assess its safety and effectiveness.

Unruptured Cerebral Aneurysm>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteNeurology

Ataxia-Telangiectasia: N-Acetyl-L-Leucine Study

We are studying whether N-Acetyl-L-Leucine can improve symptoms and quality of life for people with Ataxia-Telangiectasia. The trial will also assess the safety of this treatment.

Ataxia Telangiectasia3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Idiopathic Hypersomnia: TAK-360 Study

We are testing a new medication, TAK-360, for people with idiopathic hypersomnia to see if it helps reduce excessive daytime sleepiness and improve overall condition. The study will also monitor the safety and tolerability of the treatment.

Idiopathic Hypersomnia3-6 monthsEfficacy phase (II)Investigational MedicinesPartially RemoteNeurology

Post-COVID-19 Syndrome: Vericiguat Study

We are investigating whether Vericiguat can improve physical function and reduce fatigue in individuals with post-COVID-19 syndrome compared to a placebo. This study aims to assess various aspects of health and safety related to the treatment.

Post-COVID-19 Syndrome3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteCardiologyInternal MedicinePulmonology

COVID-19: Ibuzatrelvir Study for High-Risk Patients

We are investigating whether ibuzatrelvir can help reduce symptoms and prevent severe illness in non-hospitalized adults and adolescents with COVID-19. This study compares the medication to a placebo to see how effective it is.

COVID-193-6 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInfectious DiseasesInternal Medicine

Advanced NSCLC: Roginolisib with Dostarlimab

We are studying a new treatment combination for patients with advanced non-squamous lung cancer who have not responded to standard therapies. The trial will evaluate safety and early signs of effectiveness.

Advanced Non-Squamous Non-Small Cell Lung CancerSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncologyPulmonology

Multiple Sclerosis Spasticity: BMS-986368 Study

We are evaluating a new oral medication for spasticity in people with multiple sclerosis. The study aims to see if it improves symptoms and overall function compared to a placebo.

Multiple SclerosisMultiple Sclerosis Spasticity3-6 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesPartially RemoteNeurologyRheumatology

Cardiac Surgery: Angiotensin II vs. Noradrenaline

We are studying whether angiotensin II can better prevent kidney injury compared to noradrenaline in patients undergoing cardiac surgery. This research may help improve kidney health outcomes after surgery.

Acute Kidney Injury>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboInvestigational MedicinesPartially RemoteCardiologyInternal MedicineNephrology

Lung Cancer Treatment: Rilvegostomig vs. Pembrolizumab

We are studying a new drug, rilvegostomig, to see if it works better than pembrolizumab for patients with PD-L1-high metastatic non-small cell lung cancer. This trial aims to understand which treatment may improve survival and quality of life.

Lung CancerConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

DAVINCY Trial: (fos)Aprepitant for Nausea in Children

We are studying whether a longer duration of (fos)aprepitant can better prevent nausea and vomiting in children receiving chemotherapy. This trial compares the standard treatment with an extended regimen to find the most effective approach.

Delayed Chemotherapy Induced Nausea and VomitingConfirmation phase (III)Investigational MedicinesPartially RemoteInternal MedicineOncologyPediatrics

Hydrocortisone Treatment in Pancreatoduodenectomy Surgery

We are studying whether hydrocortisone infusions can help reduce complications after pancreatoduodenectomy surgery. This trial compares the effects of hydrocortisone to a placebo in patients undergoing this procedure.

Pancreatic Resection>2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteGastroenterologyInternal Medicine

Midgut Neuroendocrine Tumors: Lu177-Dotatate Treatment Schedule

We are studying whether giving Lu177-Dotatate every 16 weeks can lower serious side effects for patients with advanced midgut neuroendocrine tumors. This trial compares the new schedule to the standard treatment given every 8 weeks.

Small Intestine Neuroendocrine Tumor>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteGastroenterologyOncology

Non-Small Cell Lung Cancer: Sigvotatug Vedotin with Pembrolizumab

We are studying a new treatment combining sigvotatug vedotin with pembrolizumab for patients with advanced non-small cell lung cancer that has high PD-L1 levels. The goal is to see if this combination works better than pembrolizumab alone.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncologyPulmonology

Chronic Migraine: CGRP Monoclonal Antibody and Botox Combination Therapy

We are investigating whether a combination of CGRP monoclonal antibodies and Botox can reduce the number of migraine days for adults with chronic migraines. This study compares the effects of this dual therapy to a single treatment with CGRP monoclonal antibodies.

Chronic Migraine3-6 monthsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteInternal MedicineNeurology

Essential Tremor: BP1.4979 Treatment Study

We are testing a new medication, BP1.4979, for adults with essential tremor to see if it helps reduce symptoms and improve quality of life. The study will also check how safe the treatment is for patients.

Essential Tremor1-2 yearsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Premature Ejaculation: BP1.4979 Study

We are testing a new medication for adult men with primary premature ejaculation to see if it improves ejaculatory control and sexual satisfaction compared to a placebo.

Premature Ejaculation3-6 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemotePsychiatryUrology

Prostate Cancer: Ebastine with Docetaxel or Cabazitaxel

We are studying a new treatment combining ebastine with either docetaxel or cabazitaxel for men with metastatic castration-resistant prostate cancer. The goal is to evaluate how this combination affects cancer markers and PSA levels.

Hormone-Refractory Prostate Cancer3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteOncologyUrology

ABO-101 for Primary Hyperoxaluria Type 1

We are testing a new treatment, ABO-101, to see if it is safe and well-tolerated in people with Primary Hyperoxaluria Type 1. The study will also explore how the body reacts to the treatment.

Primary Hyperoxaluria>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteEndocrinologyNephrology

Moderate Atopic Dermatitis: Ruxolitinib Cream for Kids

We are studying a new cream for children and adolescents aged 6 to under 18 with moderate atopic dermatitis who haven't had success with other treatments. The trial will assess how well it works and its safety.

Atopic Dermatitis1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Alcohol Dependence: CBD and Naltrexone Study

We are investigating whether adding Cannabidiol to Naltrexone helps reduce alcohol cravings in people with alcohol dependence. The study also looks at its effects on mood, anxiety, and overall quality of life.

Alcohol Dependence>2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemotePsychiatry